Aşkın Özge, Özkoca Defne, Uzunçakmak Tuğba Kevser, Serdaroğlu Server
Cerrahpaşa Medical Faculty, Department of Dermatology and Venerology, İstanbul University-Cerrahpaşa, Istanbul, Turkey.
Dermatol Ther. 2021 Mar;34(2):e14746. doi: 10.1111/dth.14746. Epub 2021 Jan 18.
Tofacitinib is a Janus Kinase 3 inhibitor that is used in the treatment of alopecia areata. We recommended our alopecia areata patients to discontinue their tofacitinib treatment during the COVID-19 pandemic for an average of 80 days. We aimed to evaluate the drug use and the SARS-CoV-2 infection status of alopecia areata patients; and the relationships of recurrence to age, gender, treatment duration, and tofacitinib discontinuation. One-hundred and ninety-one (61.4%) patients were off the drug and 120 (38.6%) were on therapy during the pandemic. The relationship between drug discontinuation due to the COVID-19 pandemic and recurrence was statistically significant (P < .001). Statistically significant relationships of age (P = .013) and treatment duration (P < .001) to recurrence were also found. The change in the SALT score differed between the patients on therapy and off therapy during the pandemic (P < .001). A significant negative correlation was found between the change in the SALT score and treatment duration: the spearman correlation test P = .018. We concluded that the patients may continue to the tofacitinib therapy during the rest of the COVID-19 pandemic if the benefit outweighed the risk.
托法替布是一种用于治疗斑秃的 Janus 激酶 3 抑制剂。在新冠疫情期间，我们建议斑秃患者停用托法替布治疗，平均停用时间为 80 天。我们旨在评估斑秃患者的用药情况和新冠病毒感染状况；以及复发与年龄、性别、治疗持续时间和停用托法替布之间的关系。在疫情期间，191 名（61.4%）患者停药，120 名（38.6%）患者继续治疗。因新冠疫情停药与复发之间的关系具有统计学意义（P < .001）。还发现年龄（P = .013）和治疗持续时间（P < .001）与复发之间存在统计学意义的关系。疫情期间，正在治疗的患者和停药的患者之间，SALT 评分的变化存在差异（P < .001）。SALT 评分变化与治疗持续时间之间存在显著负相关：斯皮尔曼相关性检验 P = .018。我们得出结论，如果益处大于风险，患者在新冠疫情的剩余时间里可以继续使用托法替布治疗。
